Rho (D) immune globulin intravenous (Human, Cangene)

抗D免疫球蛋白（Cangene）

Report date: 2024/08/23 17:29:48

Base Information

Drug NameRho (D) immune globulin intravenous (Human, Cangene)

Drug Alias NameAnti-D immunoglobulin静脉注射Rho(D)免疫球蛋白 (Cangene/Baxter)Rho(D) Immune Globulin Intravenous (Human)抗RhoD免疫球蛋白 (Cangene/Baxter)抗D免疫球蛋白 (Cangene/Baxter) +[8]

ClassificationBiologics > Protein drugs > ImmunoglobulinBiologics > Blood components

Mechanisms of ActionBlood group Rh(D) polypeptide inhibitors

TargetsBlood group Rh(D) polypeptide

Therapy Area/IndicationsPurpura, Thrombocytopenic, IdiopathicErythroblastosis, Fetal

Global Approved IndicationsPurpura, Thrombocytopenic, IdiopathicErythroblastosis, Fetal

Approved Indications in ChinaN/A

Original Approved Country/TerritoryUnited States

Original Approved Date1995/03/24

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesCangene Corp

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsPurpura, Thrombocytopenic, IdiopathicErythroblastosis, Fetal

Inactive IndicationsN/A

Other Information

ATC CodeJ06BB01